ESC 22: Hot Line & Late-breaking Science Video Collection
Published: 24 August 2022
-
Views:
6247
-
Likes:
7
-
Views:
6247
-
Likes:
7
-
17m 13sPart 2 | Session 1 Late-breaker Discussion: The INVICTUS Trial
-
11m 27sPart 2 | Session 2 Late-breaker Discussion: The DELIVER Trial
-
14m 31sPart 2 | Session 3 Late-breaker Discussion: The REVIVED Trial
-
11m 5sPart 2 | Session 4 Late-breaker Discussion: The ADVOR Trial
-
5m 34sPart 4 | Session 1 ASCEND: Aspirin and Omega-3 Fatty Acids in Preventing Heart Failure
-
2m 29sPart 4 | Session 2 ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease
-
7m 9s
-
4m 22sPart 4 | Session 4 PACIFIC-AMI: Asundexian on Top of DAPT After Acute Myocardial Infarction
-
6m 28s
-
6m 26s
-
3m 45sPart 4 | Session 7 Artificial Intelligence Detection of Severe Aortic Stenosis
-
7m 25sPart 4 | Session 8 MOMENTUM 3: 5-year Results From HeartMate 3 LVAD Therapy
-
4m 13sPart 4 | Session 9 MASTER DAPT Results at 15M with Prof Valgimigli
-
3m 57sPart 4 | Session 10 APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID
-
3m 22sPart 4 | Session 11 The PRE18FFIR Trial: 18F-NaF PET for Vulnerable Coronary Plaque imaging After MI
-
5m 44sPart 4 | Session 12 FIDELITY: Finerenone in Pts With Chronic Kidney Disease
-
4m 44sPart 4 | Session 13 The EMPEROR-POOLED Trial: Clinical Benefits of SGLT2i in Heart Failure
-
2m 55sPart 4 | Session 14 The EMMY Trial: Empagliflozin in Patients with Acute MI
-
4m 51sPart 4 | Session 15 COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts
-
4m 59sPart 4 | Session 16 ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19
-
5m 51sPart 4 | Session 17 PERSPECTIVE: Sacubitril/Valsartan & Cognitive Function in HFmrEF & HFpEF
-
1m 29sPart 5 | Session 1 Behind the Heart: Michelle Goonasekera
-
1m 15sPart 5 | Session 2 Behind the Heart: Isla S Mackenzie
-
6m 28sPart 5 | Session 3 Behind the Heart: Douglas Bradley
-
2m 20sPart 5 | Session 4 Behind the Heart: Ashkan Shoamanesh
-
1m 22sPart 5 | Session 5 Behind the Heart: Mukul Sharma
-
1m 18sPart 5 | Session 6 Behind the Heart: Geoffrey Strange
-
4m 30sPart 5 | Session 7 Behind the Heart: Martha Gulati
-
1m 50sPart 5 | Session 8 Behind the Heart: John H Alexander
-
1m 54sPart 5 | Session 9 Behind the Heart: Renato D Lopes
-
1m 16sPart 5 | Session 10 Behind the Heart: David Newby
-
1m 43sPart 5 | Session 11 Behind the Heart: Faiez Zannad
-
1m 8sPart 5 | Session 12 Behind the Heart: Harald Sourij
-
2m 2sPart 5 | Session 13 Behind the Heart: David Berg
-
1m 11sPart 5 | Session 14 Behind the Heart: Sanjit Jolly
-
1m 20sPart 5 | Session 15 Behind the Heart: Mirvat Alasnag
-
4m 30sPart 5 | Session 16 Behind the Heart: Martha Gulati
-
2m 33sPart 5 | Session 17 Behind the Heart: Purvi Parwani
-
2m 51sPart 5 | Session 18 Behind the Heart: John McMurray
-
59sPart 5 | Session 19 Behind the Heart: Marco Valgimigli
-
6m 50sPart 6 | Session 1 REVIVED-BCIS2, RTC, FRAME-AMI by Dr Mirvat Alasnag
-
9m 51sPart 6 | Session 2 DANCAVAS, DELIVER, SECURE by Dr Purvi Parwani
-
3m 29sPart 6 | Session 3 eBRAVE-AF, CAPLA, INVICTUS by Dr Afzal Sohaib
-
7m 2sPart 6 | Session 4 TIME, SECURE, DANCAVAS by Dr Martha Gulati
-
33m 19sPart 1 | Session 1 View from the Thoraxcenter – ESC 2022 Wrap Up Nicolas M Van Mieghem, Joost Daemen
Overview
What's hot at European Society of Cardiology (ESC) Congress 22?
Stay tuned and browse our curated coverage of the latest data in cardiology.
- For a concise line up of the most awaited trials join Prof Nicolas Van Mieghem and Dr Joost Daemen and their regular View From the Thoraxcenter series.
- For a deeper dive into key clinical trial data and applicability, host, Dr Harriette Van Spall talks with principal investigators in her Late-Breaker Discussion Series.
- Short, accessible Expert Interviews conducted with select faculty focusing on data, patient care and the future of their field.
- To mark the release of the new ESC Guidelines on Cardio-Oncology, we will feature a 10-minute summary and a 10-minute live audience Q&A.
- We asked some of the most prominent researchers today about their pathways in the Behind the Heart series.
Watch our Radcliffe Premiere TV to be transported to Barcelona.
More from this programme
Part 1
View From the Thoraxcenter: Review Series
Part 2
Late-breaker Discussion Series With Dr Harriette Van Spall
Part 3
ESC Guidelines on Cardio-Oncology: Summary & Question Time
Part 4
Hot Line & Late-breaking Interviews
Part 5
Behind the Heart from Barcelona
Part 6
3 Trials That Will Change Your Practice: Reviews
Faculty Biographies
![Nicolas M Van Mieghem](https://assets.radcliffecardiology.com/s3fs-public/author/2023-03/Nicolas%20Van%20Mieghem.png?VersionId=PIxj2OOxLsAGDXGeeBjE_bjY825hUGIW)
Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
![Joost Daemen](https://assets.radcliffecardiology.com/s3fs-public/author/2024-03/Joost%20Daemen.png?VersionId=_oj8U0f7SfKyLQW01IsYreh0PvtFU9gR)
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.